- Home
- LX vs ATXS Comparison
LX vs ATXS Comparison
Compare LX & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LX
- ATXS
- Stock Information
- Founded
- LX 2013
- ATXS 2008
- Country
- LX China
- ATXS United States
- Employees
- LX N/A
- ATXS N/A
- Industry
- LX Finance: Consumer Services
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- LX Finance
- ATXS Health Care
- Exchange
- LX Nasdaq
- ATXS Nasdaq
- Market Cap
- LX 843.0M
- ATXS 676.1M
- IPO Year
- LX 2017
- ATXS 2015
- Fundamental
- Price
- LX $5.71
- ATXS $12.46
- Analyst Decision
- LX
- ATXS Buy
- Analyst Count
- LX 0
- ATXS 7
- Target Price
- LX N/A
- ATXS $30.00
- AVG Volume (30 Days)
- LX 2.6M
- ATXS 4.1M
- Earning Date
- LX 11-24-2025
- ATXS 11-12-2025
- Dividend Yield
- LX 6.79%
- ATXS N/A
- EPS Growth
- LX 86.38
- ATXS N/A
- EPS
- LX 1.28
- ATXS N/A
- Revenue
- LX $1,956,013,429.00
- ATXS N/A
- Revenue This Year
- LX $6.40
- ATXS N/A
- Revenue Next Year
- LX $17.75
- ATXS N/A
- P/E Ratio
- LX $4.46
- ATXS N/A
- Revenue Growth
- LX 0.80
- ATXS N/A
- 52 Week Low
- LX $3.01
- ATXS $3.56
- 52 Week High
- LX $11.64
- ATXS $12.55
- Technical
- Relative Strength Index (RSI)
- LX 57.79
- ATXS 84.72
- Support Level
- LX $4.93
- ATXS $11.83
- Resistance Level
- LX $5.13
- ATXS $12.16
- Average True Range (ATR)
- LX 0.26
- ATXS 0.36
- MACD
- LX 0.11
- ATXS 0.26
- Stochastic Oscillator
- LX 77.56
- ATXS 97.97
About LX LexinFintech Holdings Ltd.
LexinFintech Holdings Ltd is an online consumer finance platform and a technology-driven service provider in China. The group is engaged in online direct sales services and online consumer finance services for its customers in the PRC. Geographically, it derives revenue from China.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.